Member Info for cj62

I would find hard to align you with anyone or anything the oddity you are !!!

They do say if you say it enough you will believe it.

So pleased I didn’t fill my boots at 77p like I was encouraged to do 🤡

Touk the only thing anyone has encouraged you to do is FO. Simples !!!

It explains the heavy selling in recent days, oh to be one of the HNWI chums of RH.

To date AVCT have failed in every attempt to commercialise every single strand of their tech to date.

Excatly how many strands have avacta failed to commercialise 1. LFT and did any uk lft make it to commercialisation

To date AVCT have failed in every attempt to commercialise every single strand of their tech to date.

Excatly how many strands have avacta failed to commercialise 1. LFT and did any uk lft make it to commercialisation

Lets take black or white and say its my grey instead. I have to say if you have had children, your wife must have me terrified at the interrogation sessions you will have undetaken as to the legitimency of the off spring

Its when you realise that his closed mind is incapable of taking in information that contradicts his view that I can only wonder how angry and frustrated he must likely be in all areas of his knowledge

So why do you continue to run avacta down when the flow of information is pointing to one thing, your regurgitation of superceded/out dated information is legendary. Your pomposity knows no bounds and you seriously need help with the mental problems you have !! D-G remember when you pick your head out of his lap look in the mirror.

I've written occasionally to him since Jan 25, probably around the time SGC arrived on the agenda.

Why ?

Well as wyndrone has said AVA 6k is a waste of time so we must now wait for AVA 6103 data late H2. That trial I know will include a number of disease settings (Some more just add) with a patient popualtion of 174. That in my understanding is sufficient to provide hopefully irrifutable data that ava 6103 does in fact do what it says on the tin and i think it will so that means only another 6 months of listening to the ramblings of wyndrone aka Touk aka D-G . Thank the lord !!!!

Just a quick search on ChatGPT gave me this outcome

If I ranked them purely on current ACC-specific clinical evidence:

REM-422 – most compelling biology and strongest direct attack on the MYB driver.

Emi-Le – very impressive response data and arguably the most mature ACC efficacy dataset so far.

AVA6000 – potentially the largest commercial opportunity if the tumour-activated chemotherapy concept works broadly, but still earlier in proving efficacy.

For someone following Avacta, the key question is not whether AVA6000 can beat REM-422 in ACC specifically. The bigger question is whether AVA6000 can become a safer replacement for conventional doxorubicin across multiple tumour types, which would be a much larger market than ACC alone.

Come on energy we all know all the others have failed and avacta are trying their luck with a few more conditions

Argh D-G the FUD defender, Good one . Many a fine IPA has been consumed and many more will follow dont you worry.

The following could happen

Study the molecular architecture, linker chemistry, and payload approach

Develop a "design-around" — something structurally distinct enough to avoid infringing the sold patents, but functionally similar enough to compete in the same space

Essentially use the acquired IP as a detailed roadmap to build the next generation themselves, in parallel to Avacta's own 6103 programme

Where's Touk when we need him to educate us with his IP knowledge.

Impressive if correct and will provide a irrefutable data set when completed.

D-G so you just think avacta are after partial responses and not complete responses?

You find proving your stupidity quite easy dont you D-G

2500 x 100000 = 250 m from SGC alone + maybe TNBC 1 bill / year just from AVA 6k. thats a lot of money to just not bother with while you wait another 2 years for ava6103 to come on line. BP would pay for ava6k and a lot

Go on then toukie find that statement because you appear to be finding it hard to remember what was said a couple of weeks ago, so you know what i think you are talking utter s hi t again.

Cheery However, Emi-Le is a B7-H4-targeted ADC, whereas AVA6000 is a FAP-activated prodrug of doxorubicin, so the mechanisms and patient populations are quite different. The comparison is more about the disease area and regulatory precedent than a direct drug-to-drug comparison.

Emi-Le is a B7-H4-targeted ADC,